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Homogeneity of mesothelial and lymphatic endothelial cells,
express some markers that are presumed to be exclusive of the
endothelium was recently reported. This similarity is important
to improve the diagnosis and prognosis of malignant mesothe-
lioma (MM). Additionally, some of these markers provide the ra-
tionale for specific molecular-targeted novel therapies aimed at
MM, an aggressive malignant neoplasm, with an usually dismal
prognosis. The goal of our study was to determine the preva-
lence and expression pattern of VEGF receptor-3 (VEGFR-3)
immunoreactivity in MM and whether this immunoreactivity
occurs in different phenotypes of this neoplasm. Formalin-fixed
and paraffin-embedded samples from 29 MM cases and 5 meta-
static carcinomas were immuno-stained for VEGFR-3 according
to the streptavidin–biotin–peroxidase complex technique using a
primary antibody (Zymed Laboratories, CA, USA) diluted at
1:200. Lymphatic vessels (LV) were outlined mainly in the pe-
ripheral area surrounding the neoplasms. Blood vessels were
only rarely positive for VEGFR-3 in a pattern easily distin-
guishable from LV. In 25 out of 29 cases (86.2%) LV were
strongly positive for VEGFR-3: 14 cases (48.2%) exhibited pos-
itive VEGFR-3 reactivity in malignant cells. Epitheliod MM
showed a moderate to intense VEGFR-3 positive reaction in LV
from 8 out of 19 cases. Among the other histological subtypes,
a positive VEGFR-3 reaction was noted in malignant cells
from two cases of transitional and one case of pleomorphic
MM. Malignant cells from two out of three biphasic and one
out of three sarcomatoid MM were also positive for VEGFR-3.
Interestingly, one case of the multicystic subtype was negative
for VEGFR-3 in malignant cells and faintly positive in an occa-
sional LV. All cases of metastatic carcinoma were negative for
VEGFR-3 in the neoplastic cells. In conclusion, VEGFR-3 was
expressed in malignant cells from different subtypes of MM,
reinforcing the putative role of this marker as a potential thera-
peutic target in this group of neoplasia. Diagn. Cytopathol.
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Cancer transformation of mesothelial cells gives rise to
malignant mesothelioma (MM), an aggressive malignant
neoplasia predominantly of the pleura and closely associ-
ated to asbestos exposure. Recently, simian virus (SV40)
infection was also recognized as a causative agent of MM
oncogenesis. In vitro evidence exists, showing that SV40-
exposed mesothelial cells are particularly susceptible to
malignant transformation; and in vivo observation showed
that SV40 is able to produce MM when injected in rodent
visceral cavities.1
MM incidence is increasing worldwide, which is
believed to be a consequence of a more widespread expo-
sure to asbestos. Because of the relentless, aggressive
behavior of MM, there is a great interest among Public
Health authorities and the public regarding this epidemic.2
Prognosis is usually dismal, worse in male patients, with
median survival around 12 months from the time of diag-
nosis and no measurable improvement with traditional
forms of treatment.2,3 Novel therapies with Alimta and
Cisplatinum only marginally improve survival, but may
improve the quality of life in terminal patients.
Accurate diagnosis is crucial for appropriate therapeutic
intervention, but, not infrequently, patients with MM are
misdiagnosed at the time of their first consultation, such
delays generally occurring in centers where MM is
uncommon.4 Cytologic diagnosis can be achieved rapidly
and accurately depending on the experience of the cytopa-
thologist. Nevertheless, negative cytological results of
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pleural effusion do not exclude the possibility of MM.5
Video-assisted toracoscopic (VATS) biopsy can often es-
tablish the diagnosis of malignancy, but sometimes do not
allow a definitive diagnosis of MM.3 Histopathological di-
agnosis can be difficult because MM exhibits a number of
morphological appearances. Additionally, the serous
membranes of the three body cavities are commonly
invaded by metastasis, and often display mesothelial
hyperplasia and florid reactive fibrosis.6 Rarely primary
pleural sarcomas, can mimic MM.5,6 The histological type
of MM seems to be related to the prognosis, i.e., the tubu-
lopapillary variant of epithelial type has a more favorable
prognosis than sarcomatoid type.7 As both the cytological
and histological diagnosis of MM can be difficult when
based only in routine staining, immunohistochemical
markers should be considered in most instances.8–10 A
number of studies have suggested different panels of im-
munohistochemical markers, which are useful in routine
practice, to distinguish MM from metastatic carcinoma,
but less effective in separating benign, reactive conditions
from malignant lesions.11–13
MM cases have a tendency to remain within the frame-
work of the serosa, a thin, expandable membrane, rich in
lymphatics. Metastases are less common than in lung car-
cinomas, including pleurotropic tumors growing along the
subserosal layer, the so- called pseudo- mesotheliomatous
carcinoma.14 When MM metastasize, they usually follow
the lymphatic pathway, but rarely they may give distant
metastasis, via the blood vessels. The underlying factors
for these preferential routes are not known, but may be
related to the ability of MM tumor cells to survive in dif-
ferent microenvironments or their ability to interact with
the stroma.15 In 1999, Ohta et al. showed that lymphan-
giogenesis was an important feature in MM and it was
related to the production of VEGF-C and its receptor:
VEGFR-3.16 More recently, Ando et al.17 described the
homogeneity of mesothelial and lymphatic endothelial
cells in expressing some markers originally believed to be
exclusive of endothelium. These authors, with an elegant
in vitro study, reported that cultured mesothelial and lym-
phatic endothelial cells expressed VEGFR-3, LYVE-1,
and Prox-1 lymphatic-specific markers. Additionally, D2-
40 and Podoplanin, two other specific lymphatic markers
were also reported to be highly sensitive and specific to
recognize epithelioid mesothelioma.18–20 In a study of
Nerve Growth Factor Receptors, Davidson et al.21 found
that p-trK-a receptor and to a less extent p75, distributed
preferentially along the MM blood vessels, including lym-
phatics.
These new molecular players in the mesothelioma sce-
nario certainly increased the expectations in the diagnosis
and prognosis arenas, but also open an important route
for emerging strategies in the translational therapy of
MM.22 Consider for example the vascular endothelial
growth factor (VEGF) family, which is involved in the
angiogenesis and lymphangiogenesis switch in health and
disease. Preliminary results of growth inhibitors agents
targeting VEGF members, ligands and their receptors, are
encouraging as therapeutic option for MM.23
The purpose of our study was to determine the immuno-
histochemical reactivity of VEGF receptor-3 (VEGFR-3)
in human MM cases and find out whether its prevalence and
distribution pattern is similar among the different histologi-
cal subtypes of MM.
Materials and Methods
Patients and Tumor Samples
Tissue samples were retrospectively obtained from the
Department of Pathology, Norwegian American Hospital,
Chicago, IL and the University Michigan Hospital and
Clinics, Ann Arbor, MI. Formalin-fixed and paraffin-em-
bedded samples of 29 MM cases and 5 pleurotropic meta-
static adenocarcinomas were recovered. All cases were
reviewed by two of us (CB and CM), without prior
knowledge of the original treating physician diagnosis or
classification, according to histological, immunocytochem-
ical and ultrastructural criteria previously described.24
Tumors selected for this study were further classified fol-
lowing the WHO recommendations for certain recogniz-
able patterns such as tubulo-papillary, small cell, clear
cell, deciduoid, transitional, pleomorphic, lympho-histio-
cytoid, and microglandular.25
A total of 29 cases were obtained: 21 from pleura (3
women and 18 men) and 6 from peritoneum (3 women
and 3 men). The age of the patients with pleural MM
ranged from 19 to 85 years old (mean 62.4) and from
peritoneal MM from 17 to 78 (mean 50.2). Five cases of
pleurotropic metastatic carcinoma of the lung were also
included for comparison with MM.
VEGFR-3 Immunohistochemical Procedure
Immunohistochemical reaction was performed according
to streptavidin–biotin–peroxidase complex technique
using a primary antibody raised against VEGFR-3
(Zymed Laboratories, CA) diluted 1:200. In brief, depar-
affinized and rehydrated sections were immersed in
0.01M citrate buffer (pH 6.0) and microwaved at 700 W
for 15 min; then the slides were incubed with 3% hydro-
gen peroxide in methanol for 10 min and with Ultravision
Block solution (Neomarkers, Freemont, CA) for 10 min
also, at room temperature, before incubating 30 min with
the primary antibody. Sections were sequentially washed
in PBS 13 with 0.02% Tween 20 and incubated with bio-
tinylated goat anti-polyvalent antibody for 10 min, strep-
tavidin peroxidase for 10 min, and developed with 3,30-
diamino-benzidine for 15 min. The slides were counter-
stained with Mayer hematoxylin and mounted with Entel-
lan (Merck, Dermstadt, Germany). Negative controls of
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reactions were performed with omission of primary anti-
body; as positive controls we have used invasive ductal
breast carcinoma tissue as advised by the manufacturer.
Evaluation of VEGFR-3 Positive Reactions
Immunohistochemical VEGFR-3 expression was consid-
ered positive on cytoplasm of the endothelial lymphatic
cells and malignant cells.
We semi-quantitatively assessed the distribution of the
marker in decorated cells according to the following grad-
ing system: negative (), absence of expression; slight
positive staining (þ), expression in up to 10% of cells;
moderate positive (þþ), when the positive reaction was
observed in 10% and until 50% of cells; strongly positive
(þþþ), when the positive reaction was expressed in more
than 50%. The assessment of positive reactions was per-
formed in hot spot areas where proliferating vascular
structures and epithelial malignant cells were present and
stained, accordingly previously reported.26
Correlation of VEGFR-3 Expression and
Mesothelioma Phenotype
VEGFR-3 results were correlated with the different sub-
types of MM, age, sex, and localization.
Results
The majority of LV from MM cases were strongly posi-
tive for VEGFR-3, including 25 out of 29 (86.2%) cases.
VEGFR-3 positive LV were more prevalent and more
intensily outlined in tumor with dense desmoplastic
stroma, including abundant collagen separating the malig-
nant cells. Conversely, LV were lesser prominent in well-
differentiated epithelioid MM, including tubulopapillary
tumors rich in fibrovascular cores, supporting outcrops of
cuboidal neoplastic cells. Indeed, the negative and slightly
positive VEGFR-3 reactions were for the most part
observed in these cases. Just one of three sarcomatoid
MM showed a VEGFR-3 reaction that was faintly posi-
tive. The lymphatics in this case appeared either as large
and tangled vessels, or as small slit-like spaces, difficult
to discern with the H&E stain.
Once they had been clearly outlined with the positive
VEGFR-3 reaction, LV appeared as microvascular tufts
without RBCs in their lumina, both at the periphery of
neoplasms and as part of their supporting stroma (Fig. 1)
Peritumoral and intratumoral LV outlined by VEGFR-3
occurred as closely stretched linear structures, with dif-
ferent dimensions, predominantly elongated in shape and
containing few RBCs in their collapsed lumina (Fig. 2).
Fourteen cases (48.2%) exhibited positive VEGFR-3
staining in the malignant cells (Fig. 3); in seven cases
the VEGFR-3 expression was focal: three epithelioid,
two transitional, one sarcomatoid and one biphasic MM.
The epitheliod subtype of MM showed VEGFR-3 posi-
tive reaction in malignant cells from 8 out of 19 cases
(42%). These cases showed negative to slight Immunor-
eactivity in their LV outlined by VEGFR-3. From the
others MM cases, positive VEGFR-3 reactions in malig-
nant cells were observed in the two cases of transitional
and one case of anaplastic subtype (Fig. 4). Two out of
three biphasic and one out three sarcomatoid cases also
exhibited VEGFR-3 positivity in malignant cells. Inter-
estingly, the case of multicystic subtype was negative
for VEGFR-3 in malignant cells and faintly positive in
few LV (Fig. 5).
Table I depicts the scores of all VEGFR-3 reactions,
correlating the histological subtype of MM with VEGFR-
3 expression in both malignant cells and lymphatic endo-
thelial cells. Epithelloid MM was the most common histo-
logical type observed, occurring in 19 out of 29 (65.5%)
Fig. 1. Transitional MM, with no readily apparent lymphatic vessels
(LV)-H&E (3400). [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Fig. 2. Closely compressed VEGFR-3-positive intratumoral lymphatics
in transitional MM-VEGFR-3 (3400). [Color figure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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cases. These tumors exhibited remarkably bland cytomor-
phologic characteristics, although their architectural pat-
tern included a wide spectrum of solid, papillary, tubulo-
papillary, and adenomatoid areas. Vascularity of these
neoplasms was extremely variable, including LV channels
that could not be readily recognizable, without the help of
the VEGFR-3 immunostain. VEGFR-3 clearly outlined
lymphatic vessels (LV) mainly in areas surrounding these
neoplasms, including adipose tissue. Intra-tumoral LV in
epithelioid MM were predominantly represented by com-
pressed structures stained positively for VEGFR-3
(Fig. 6). Thick wall blood vessels were only rarely positive
for VEGFR-3. All malignant cells from metastatic pleuro-
tropic adenocarcinomas were negative for VEGFR-3.
The LV density showed a positive correlation between
VEGFR-3 stained cases and MM subtypes as a whole:
only 4 out of 29 cases (13.8%) were negative for
VEGFR-3. Except for epitheliod MM, the other subtypes
were represented by very few cases, which limited the
correlation between VEGFR-3 expression and histological
differentiation. Despite this limitation, sarcomatoid, transi-
tional, biphasic, and pleomorphic MM subtypes displayed
a rich lymphatic vasculature strongly reactive for
VEGFR-3.
Discussion
The involvement of vascular growth factor family (VEGF
A, -B, -C, -D, and placenta growth factor – PIGF) in
angiogenic and lymphangiogenic phenomena is well
established and crucial for the proliferation of mesothelial
cells and the growth of MM.16–21 The potential anti-can-
cer therapy using inhibitors targeted to VEGF family
appears as a rational tool for several tumors including
MM.23 VEGF, the best known angiogenic factor plays a
role in the progression of MM since it is implicated in
tumor-associated microvascular hyperpermeability and
carcinogenesis, which results in malignant effusions.27
Heparanase, a 65 KDa active precursor, after proteolytic
cleavage yields an 8 and a 50 kDa subunit, which hetero-
dimerize to form an active endogycosidase, capable of
releasing VEGF-sulfate bound to the extracellular matrix
(ECM). This enzyme not only plays a significant role in
cancer metastasis and angiogenesis, but is also believed to
play a role in malignant effusions caused by MM.28
The few informative studies in series of human tumors
encouraged us to evaluate the expression of VEGFR-3 in
MMs. Our findings reinforce previous studies that had
demonstrated lymphangiogenesis in MM.13 VEGFR-3
expression in lymphatic vessels was demonstrated in
86.2% of our cases and in 10 out of 25 (40%) cases with
lymphangiogenesis we observed a high number of LV.
These findings corroborate the aggressive biological
Fig. 3. Epithelioid MM, with poorly formed septa, outlined by com-
pressed tumor cells-H&E (3400). [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
Fig. 4. Peritumoral VEGFR-3 positive lymphatics surrounding epithe-
lioid MM tumor cells negative for VEGFR-3-VEGFR-3 (3400). [Color
figure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
Fig. 5. VEGFR-3-positive tumor cells in pleomorphic MM-VEGFR-3
(3400). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
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behavior of this group of neoplasias as previously demon-
strated in the literature.2,3
Additionally, recent publications describing the expres-
sion of lymphatic endothelial cell markers by the mesothe-
lium constitute an exciting trend to be explored.18–20 None-
theless, we did not investigate the VEGFR-3 expression
with the purpose to add one more marker to the already
extensive panel aiming to distinguish MM from its mimics.
Our goal was to ascertain the VEGFR-3 expression in MM,
including its different subtypes, in order to establish the
relationship between tumor differentiation and this marker.
This is of interest because VEGF-C and its receptor
VEGFR-3 are coexpressed in mesothelial cell lines.
VEGF-C acts as a potent mitogen, which stimulates lym-
phangiogenesis. In addition, a functional VEGF-C auto-
crine growth loop exists in mesothelial cells and is con-
sidered a promising therapeutic target.29,30 However, it is
well known that the specificity of various markers in ma-
lignant MMs should be assessed according to histological
subtypes because the antigenicity can be severely affected
by heterogeneity and dedifferentiation, consequent to
overexpression or underexpression of certain antigens.4,11
Molecular signaling pathways in MM are nowadays a
complex and motivating area of research with clear use-
fulness in routine conditions. The rising incidence and
consistent aggressiveness of MM needs urgent improve-
ment to patients’ therapy. The available staging scores
have limited the prognostic value of these molecular
markers, and the main application of these molecular sys-
tems, e.g., the selection of patients for clinical trials.31
This is the most compelling reason to study alternative
options linked to molecular pathways, such as research on
VEGF family, including KDR; heparanase (HPSE-1), ba-
sic fibroblastic growth factor (bFGF), epidermal growth
factor receptor, cell cycle control proteins, insulin growth
factor, cyclooxyenase-2, and other molecules. These stud-
ies should provide rationale for better informed MM ther-
apeutic decisions in the near future as is already the case
in more common neoplasms, such as breast carcinoma.32
Our results have corroborated, in part, the observations
of Ando et al. who demonstrated the similarities between
mesothelial and endothelial cells with regards to their an-
tigenicity.17 The usefulness of this parallel immediately
endorsed its application in routine conditions to optimize
the discrimination between MM and adenocarcinoma, a
puzzling point in daily routine of surgical pathology prac-
tice.15–17 More than the differential diagnostic approach,
the correspondence between mesothelium-originated ma-
lignant neoplasia and their LV in regards to endothelial
molecular markers may provide a useful target for novel
cancer therapies.19 Indeed, this would be a welcome de-
velopment, given MM’s grim prognosis and the dismal
results with existing treatment protocols, based on various
combinations of surgery, radiation and chemotherapy.
MM is one of numerous malignant neoplasms where
VEGF receptors’ expression has been demonstrated.16,23
Our results further reinforce these observations, since
VEGFR-3 was identified in most cases of MM independ-
ently of the histological subtype. We recently reported the
expression of VEGFR-3 in lymphatic and blood vessel
cells, and myoepithelial cells from ductal invasive breast
carcinoma, but not in malignant cells.26,32 This is quite
provoking, because it reinforces the hypothesis that
VEGFR-3 signaling could act by a paracrine and also an
autocrine pathways in MM.30 Moreover, these previous
reports are in accordance with the present finding of ab-
sence of VEGFR-3 expression in all cases of metastatic
carcinomas studied as controls. Although not a purpose of
our study, elucidation of common factors inducing lym-
phangiogenesis separately or in combination with micro-
Table I. Correlation Between the Mesothelioma Subtypes and VEGFR-3 Expression in Malignant
Cells and Lymphatic Vessels
Histologic subtype
VEGFR-3 reaction malignant cells VEGFR-3 reaction lymphatic vessels
Negative Positive Negative 1þ 2þ 3þ
Epithelioid (n ¼ 19) 11 8 4 6 6 3
Sarcomatoid (n ¼ 3) 2 1 0 1 0 2
Biphasic (n ¼ 3) 1 2 0 0 0 3
Transitional (n ¼ 2) 0 2 0 1 0 1
Pleomorphic (n ¼ 1) 0 1 0 0 0 1
Multicystic (n ¼ 1) 1 0 0 0 1 0
Fig. 6. Desmoplastic region from sarcomatoid MM, without positivity
for VEGF-3-VEGFR-3 (3400). [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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vasculature angiogenesis, seems to be another emerging
area, ripe for investigation. In conclusion, the demonstra-
tion that VEGFR-3 expression in MM is not restricted to
the epithelioid variant, but it is expressed also in sarcoma-
toid and biphasic types, renders VEGFR-3 as a potential
therapeutic target in this very aggressive human cancer,
thus justifying its further investigation.
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